Bill Ackman's two co-leads supply 17% of Precision Neuroscience's $250 million round

Only one slice of the $250 million has a size attached, or rather one pair of related checks: Pershing Square and the Ackman Oxman Institute supplied $42.5 million ^[6], or 17% of the round ^[22]. The remaining $207.5 million ^[23] came from the unnamed life sciences fund that co-led ^[3] and the nine other investors ^[5]. The company did not disclose how that balance split.

The split decides whether generalist money is paying for the costly commercial stage of brain implants. If the unnamed specialist fund wrote most of the $207.5 million, specialists are still carrying the risk, and ARK Invest and Mubadala Capital ^[5] are names on the register. If ARK, Mubadala and Duquesne Family Office wrote large checks, the generalist case holds. I think the evidence supports a narrower claim. The one non-specialist check with a number on it is Ackman's, and TechFundingNews described it as a rare private check from one of Wall Street's most vocal activist investors ^[28]. "Precision has the team, technology, and ambition to be a leader in BCI, and we are therefore delighted to invest in the company," Ackman said ^[14].

The money pays for more FDA review. Layer 7 is a film thinner than a human hair that sits on the brain's surface ^[15]. It is cleared for up to 30 days of use ^[7], and pulse2 notes that the clearance should not be read as approval for every future clinical application ^[8]. Precision says the Series D will carry the device through later stages of FDA review and pay for commercial infrastructure ^[9]. According to TechFundingNews, Mager has said a permanent device could take years ^[17].

At just over $1 billion ^[16], Precision is valued at roughly 2.3 times the $430 million it has raised ^[24]. If that is a post-money figure, the new investors bought about a quarter of the company ^[25]. Neuralink raised $600 million at $9 billion last year ^[18], nearly nine times Precision's mark ^[26]. Science Corporation's $230 million Series C in March 2026 valued it at $1.5 billion ^[20]. Synchron has raised $345 million in all after a $200 million Series D in November 2025 ^[19], $85 million less than Precision ^[27].

Precision's spending shows what it will build itself. It owns a microelectromechanical systems plant in Texas that makes its electrode arrays ^[12], so electrode production is a fixed cost it carries before any permanent clearance. The surgical system goes to Medtronic, through a commercial partnership to fit Layer 7 into an established neurosurgical platform ^[11]. "The next phase of BCI will be defined by more than technology alone. We have built the clinical network, regulatory position, and manufacturing base that leadership in this field requires," said Michael Mager, the co-founder and chief executive ^[13].

TechFundingNews wrote that the question deciding the category is whether any of these companies can get a permanent, fully implantable device through the FDA ^[21]. Until Layer 7 clears that bar, a buyer at $1 billion is paying for more than 100 procedures at 18 institutions ^[10] and a 30-day clearance ^[7].